Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 10/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749419 | 1.00 | SRD5A2 (0.45) | SRD5A2ESR1ARESR2SRD5A1 | |
| SCHEMBL3753999 | 1.00 | SRD5A2 (0.45) | SRD5A2ESR1ARESR2SRD5A1 | |
| SCHEMBL13046034 | 0.80 | SRD5A2 (0.68) | SRD5A2ESR1ARESR2SRD5A1 | |
| SCHEMBL8607966 | 0.80 | ESR1 (0.45) | SRD5A2ESR1ARESR2SRD5A1 | |
| SCHEMBL3749381 | 0.78 | SRD5A2 (0.39) | SRD5A2ESR1ARESR2SRD5A1 | |
| SCHEMBL4208937 | 0.77 | SRD5A2 (0.34) | SRD5A2 | |
| SCHEMBL4210328 | 0.77 | SRD5A2 (0.34) | SRD5A2 | |
| SCHEMBL3671812 | 0.77 | SRD5A2 (0.44) | SRD5A2ESR1ARESR2SRD5A1 | |
| SCHEMBL3754980 | 0.75 | ESR1 (0.37) | SRD5A2ESR1ARESR2SRD5A1 | |
| SCHEMBL11238456 | 0.74 | ESR1 (0.52) | SRD5A2ESR1ARESR2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
| EP-2167525-A2 | 17ß-CYANO-19-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008152112-A2 | 17ß-CYANO-19-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | SRD5A2 15/4885ESR1 42/4885AR 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.